+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease

Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease

Biology of Blood and Marrow Transplantation 16(3): 311-319

Allogeneic bone marrow transplantation (BMT) is an effective therapy for hematologic malignancies. However graft-versus-host disease (GVHD) is a major limiting factor for a successful patient outcome. GVHD is a result of alloimmune responses of donor T lymphocytes attacking the recipient's cells and tissues. Chemokine receptor CCR5 plays a role in solid organ allograft rejection and mediates murine GVHD pathogenesis. Herein, we report that infiltrating lymphocytes in the skin of human acute GVHD (aGVHD) samples are predominantly CCR5(+) T cells. In addition, we characterized the features of the CCR5 expression on alloreactive T lymphocytes. We found that the CCR5(+) population exhibits the characteristics of the activated effector T cell phenotype. CCR5 expression is upregulated upon allogenic stimulation, and CCR5(+) cells are proliferating with coexpression of T cell activation markers. Furthermore, the activated T cells producing inflammatory cytokine tumor necrosis factor (TNF)alpha, interleukin (IL)-2, or interferon (IFN)-gamma, are positive for CCR5. Thus, CCR5 is a marker for GVHD effector cells and CCR5(+) T cells are active participants in the pathogenesis of human aGVHD.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052051618

Download citation: RISBibTeXText

PMID: 20025985

DOI: 10.1016/j.bbmt.2009.12.002

Related references

Alterations in chemokine receptor CCR5 expression on blood dendritic cells correlate with acute graft-versus-host disease. Transplantation 96(8): 753-762, 2013

Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. Blood 115(23): 4914-4922, 2010

Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses. International Journal of Hematology 98(3): 293-299, 2013

Chemokine Receptor-5 and Graft-versus-Host Disease. Zhongguo Shi Yan Xue Ye Xue Za Zhi 23(3): 883-887, 2015

Chemokine receptor blockade in graft-versus-host disease. Lancet. Oncology 13(8): E333, 2012

IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation. Journal of Immunology 189(4): 2033-2042, 2012

Inhibition of graft-versus-host disease by a distamycin analogue that interferes with chemokine receptor function. Blood 94(10 Suppl. 1 Part 1): 392a, 1999

The role of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in the development of graft-versus-host-disease. Blood 102(11): 944a-945a, 2003

CC chemokine receptor 2 expression in donor cells serves an essential role in graft-versus-host-disease. Journal of Immunology 171(9): 4875-4885, 2003

Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver. Biology of Blood and Marrow Transplantation 21(12): 2069-2078, 2015

CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. Blood 122(5): 825-836, 2013

Down regulation of CXC chemokine receptor 3 impedes the ability of anti-CXCR3 antibody to block graft-versus-host disease. 2007

Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. Transplantation Proceedings 23(1 Pt 1): 521-524, 1991